Ptc Therapeutics Stock Today
| PTCT Stock | USD 25.41 0.56 2.16% |
Performance0 of 100
| Odds Of DistressLess than 36
|
PTC Therapeutics is selling for under 25.41 as of the 23rd of April 2024; that is -2.16 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 25.17. PTC Therapeutics has about a 36 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for PTC Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of March 2024 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of June 2013 | Category Healthcare | Classification Health Care |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. The company has 76.61 M outstanding shares of which 10.26 M shares are at this time shorted by private and institutional investors with about 11.39 trading days to cover. More on PTC Therapeutics
Moving against PTC Stock
| 0.51 | ITCI | Intracellular Th Financial Report 2nd of May 2024 | PairCorr |
PTC Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. PTC Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding PTC Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | FACS MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, ARCA Biotechnology, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering PTC Therapeutics report their recommendations after researching PTC Therapeutics' financial statements, talking to executives and customers, or listening in on PTC Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering PTC Therapeutics. The PTC consensus assessment is calculated by taking the average forecast from all of the analysts covering PTC Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to PTC Therapeutics' liquidity, profitability, solvency, and operating efficiency, PTC Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of PTC Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PTC Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to PTC Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand PTC Therapeutics' financial leverage. It provides some insight into what part of PTC Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PTC Therapeutics (PTCT) is traded on NASDAQ Exchange in USA. It is located in 100 Corporate Court, South Plainfield, NJ, United States, 07080 and employs 988 people. PTC Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.99 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate PTC Therapeutics's market, we take the total number of its shares issued and multiply it by PTC Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. PTC Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 76.61 M outstanding shares of which 10.26 M shares are at this time shorted by private and institutional investors with about 11.39 trading days to cover.
PTC Therapeutics currently holds about 288.43 M in cash with (158.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01.
Check PTC Therapeutics Probability Of Bankruptcy
Ownership AllocationPTC Therapeutics shows a total of 76.61 Million outstanding shares. The majority of PTC Therapeutics outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to secure positions in PTC Therapeutics to benefit from reduced commissions. Therefore, outside corporations are subject to a different set of regulations than regular investors in PTC Therapeutics. Please pay attention to any change in the institutional holdings of PTC Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check PTC Ownership Details
PTC Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of PTC Therapeutics jumping above the current price in 90 days from now is about 86.86%. The PTC Therapeutics probability density function shows the probability of PTC Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.5162 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, PTC Therapeutics will likely underperform. Additionally, pTC Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of PTC Therapeutics to move above the current price in 90 days from now is about 86.86 (This PTC Therapeutics probability density function shows the probability of PTC Stock to fall within a particular range of prices over 90 days) .
PTC Stock Institutional Holders
Institutional Holdings refers to the ownership stake in PTC Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of PTC Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing PTC Therapeutics' value.| Instituion | Recorded On | Shares | |
| Franklin Resources Inc | 2023-12-31 | 1.4 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.2 M | |
| Jacobs Levy Equity Management, Inc. | 2023-09-30 | 1.1 M | |
| Blackstone Inc | 2023-12-31 | 1.1 M | |
| Goldman Sachs Group Inc | 2023-12-31 | 1.1 M | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 998.3 K | |
| Adage Capital Partners Gp Llc | 2023-12-31 | 892.2 K | |
| Pictet Asset Manangement Sa | 2023-12-31 | 866.6 K | |
| D. E. Shaw & Co Lp | 2023-09-30 | 840.8 K | |
| Wellington Management Company Llp | 2023-12-31 | 9.8 M | |
| Vanguard Group Inc | 2023-12-31 | 8.8 M |
PTC Therapeutics Historical Income Statement
PTC Therapeutics Income Statement is one of the three primary financial statements used for reporting PTC's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of PTC Therapeutics revenue and expense. PTC Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, PTC Therapeutics' Total Operating Expenses is comparatively stable compared to the past year. Reconciled Depreciation is likely to gain to about 204.5 M in 2024, whereas EBITDA is likely to drop (118.5 M) in 2024. View More FundamentalsPTC Stock Against Markets
Picking the right benchmark for PTC Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in PTC Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for PTC Therapeutics is critical whether you are bullish or bearish towards PTC Therapeutics at a given time. Please also check how PTC Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in PTC Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
PTC Therapeutics Corporate Directors
PTC Therapeutics corporate directors refer to members of a PTC Therapeutics board of directors. The board of directors generally takes responsibility for the PTC Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of PTC Therapeutics' board members must vote for the resolution. The PTC Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Emma Reeve | Independent Director | Profile | |
| Stephanie Okey | Independent Director | Profile | |
| Ronald Renaud | Director | Profile | |
| Dawn Svoronos | Director | Profile |
How to buy PTC Stock?
Before investing in PTC Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in PTC Therapeutics. To buy PTC Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of PTC Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase PTC Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located PTC Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased PTC Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as PTC Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.
Already Invested in PTC Therapeutics?
The danger of trading PTC Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of PTC Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than PTC Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile PTC Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether PTC Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if PTC Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ptc Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Ptc Therapeutics Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for PTC Stock analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets |
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 12.531 | Quarterly Revenue Growth 0.834 | Return On Assets (0.12) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.